Search Result
Results for "
pain disorders
" in MedChemExpress (MCE) Product Catalog:
3
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-13681
-
|
Glucocorticoid Receptor
|
Inflammation/Immunology
|
Methylprednisolone acetate, a prednisolone derivative, is a corticosteroid hormone. Methylprednisolone acetate can relieve pain and swelling that occurs with arthritis and other joint disorders in vivo .
|
-
-
- HY-160616
-
-
-
- HY-143481
-
|
Sodium Channel
|
Neurological Disease
|
Nav1.8-IN-2 (compound 35A) is a potent Nav1.8 inhibitor with an IC50 value of 0.4 nM. Nav1.8-IN-2 can be used for researching pain disorders, cough disorders, and acute and chronic itch disorders .
|
-
-
- HY-153458
-
|
Orexin Receptor (OX Receptor)
|
Neurological Disease
Metabolic Disease
|
Orexin receptor modulator-1 is an orexin receptor modulator. Orexin receptor modulator-1 can be used for the research of substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension .
|
-
-
- HY-160540
-
-
-
- HY-B0161E
-
(Rac)-Duloxetine hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
(±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research .
|
-
-
- HY-145453
-
|
Others
|
Inflammation/Immunology
Cancer
|
Propacetamol is an analgesic agent. Propacetamol also is a precursor form of paracetamol. Propacetamol can be used in postoperative pain, acute trauma and gastrointestinal disorders .
|
-
-
- HY-108292
-
|
Others
|
Cancer
|
Propacetamol hydrochloride is an analgesic agent. Propacetamol hydrochloride also is a precursor form of paracetamol. Propacetamol hydrochloride can be used in postoperative pain, acute trauma and gastrointestinal disorders .
|
-
-
- HY-118158
-
|
FAAH
|
Neurological Disease
|
FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC50s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders .
|
-
-
- HY-147563
-
|
RET
|
Cancer
|
RET-IN-17 is a potent inhibitor of RET. RET-IN-17 has the potential for the research of pain associated with IBS and other gastrointestinal disorders and for the research of cancers with constitutive RET kinase activity (extracted from patent WO2016038552A1, compound 1) .
|
-
-
- HY-145997
-
|
Mas-related G-protein-coupled Receptor (MRGPR)
|
Inflammation/Immunology
|
MRGPRX4 modulator-1 (compound 31-2) is a potent mas-related g-protein receptor X4 (MRGPR X4) modulator, with antagonist activity of IC50 < 100 nM for MRGPR4. MRGPRX4 modulator-1 can be used for researching MRGPR X4 dependent diseases such as itch, pain, and autoimmune disorders .
|
-
-
- HY-145086
-
|
Others
|
Metabolic Disease
|
R-PSOP is highly potent and selective nonpeptidic NMUR2 antagonist. R-PSOP binds to NMUR2 with the Kis of 52 and 32 nM for the human and rat NMUR2, respectively. R-PSOP shows moderate CNS penetration. R-PSOP can be used for the research of the eating disorders, obesity, pain, and stress-related disorders .
|
-
-
- HY-103462
-
|
FAAH
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
TC-F2 is a reversible non-covalent binding inhibitor of fatty acid amide hydrolase (FAAH) with an IC50 of 28 nM. FAAH is involved in many human diseases, particularly cancer, pain and inflammation as well as neurological, metabolic and cardiovascular disorders .
|
-
-
- HY-153548
-
-
-
- HY-144827
-
|
Cannabinoid Receptor
|
Neurological Disease
Metabolic Disease
|
AM8936 acts as a balanced and potent cannabinoid receptor type-1 (CB1) agonist in functional assays (EC50s of 8.6 and 1.4 nM for rCB1 and hCB1, respectively). AM8936 exhibits high affinity for rat CB1 (rCB1) with Ki of 0.55 nM. AM8936 is a potent and efficacious CB1 agonist in vivo. AM8936 can be used for the research of CNS and metabolic disorders, pain, glaucoma, etc .
|
-
-
- HY-103520
-
|
GABA Receptor
|
Neurological Disease
|
DS2 is a selective positive allosteric modulator of δ-GABAA receptor. DS2 selectively potentiates GABA responses mediated by α4β3δ receptor. DS2 does not enhance activity at α4β3γ2 and α1β3γ2 receptors. DS2 relieves pain and has the potential for sleep disorders research .
|
-
-
- HY-157802
-
|
Sodium Channel
|
Neurological Disease
|
LTGO-33 is a potent and selective voltage-gated sodium channel NaV1.8 inhibitor. LTGO-33 inhibits NaV1.8 in the nM potency range and exhibits over 600-fold selectivity against human NaV1.1-NaV1.7 and NaV1.9. LTGO-33 exhibits state-independent inhibition with similar potencies on channels in the closed and inactivated conformations. LTGO-33 inhibits native TTX-R NaV1.8 currents in non-human primate and human DRG neurons, where it reduces action potential firing. LTGO-33 can be used for pain disorders research .
|
-
-
- HY-119864
-
-
-
- HY-N2428
-
|
FAAH
|
Neurological Disease
|
N-(3-Methoxybenzyl)Palmitamide is a promising inhibitor of FAAH for the treatment of pain, inflammation and CNS degenerative disorders .
|
-
-
- HY-153471
-
-
-
- HY-157496
-
|
Prostaglandin Receptor
|
Others
|
EP3 antagonist 7 (Compound II) is an EP3 receptor antagonist. EP3 antagonist 7 can be used in the study of itching, pain, dysuria or stress disorders .
|
-
-
- HY-162246
-
|
Sodium Channel
|
Cardiovascular Disease
Neurological Disease
|
Nav1.8-IN-5 (Example 1) is a voltage-gated sodium channel Nav1.8 inhibitor. Nav1.8-IN-5 can be used for Nav1.8-mediated diseases, such as pain and pain-related disorders, as well as cardiovascular diseases (such as atrial fibrillation) research .
|
-
-
- HY-13985
-
|
Sodium Channel
|
Neurological Disease
|
Nav1.7 inhibitor (compound II), a sulfonamide, is a potent Nav1.7 inhibitor. Nav1.7 inhibitor has the potential for a wide range of disorders, particularly pain .
|
-
-
- HY-13681R
-
|
Glucocorticoid Receptor
|
Inflammation/Immunology
|
Methylprednisolone acetate (Standard) is the analytical standard of Methylprednisolone acetate. This product is intended for research and analytical applications. Methylprednisolone acetate, a prednisolone derivative, is a corticosteroid?hormone. Methylprednisolone acetate can relieve pain and swelling that occurs with arthritis and other joint disorders in vivo .
|
-
-
- HY-13681S
-
|
Glucocorticoid Receptor
Isotope-Labeled Compounds
|
Inflammation/Immunology
|
Methylprednisolone acetate-d6 is the deuterium labeled Methylprednisolone acetate (HY-13681). Methylprednisolone acetate, a prednisolone derivative, is a corticosteroid hormone. Methylprednisolone acetate can relieve pain and swelling that occurs with arthritis and other joint disorders in vivo .
|
-
-
- HY-135816
-
|
Casein Kinase
Pim
|
Inflammation/Immunology
Cancer
|
CK2/PIM1-IN-1 is an inhibitor of CK2 and PIM1, with IC50s of 3.787 μM and 4.327 μM for CK2 and PIM1, respectively. CK2/PIM1-IN-1 is developed for the research of proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders .
|
-
-
- HY-B0161ES
-
(Rac)-Duloxetine-d3 (hydrochloride)
|
Serotonin Transporter
|
Neurological Disease
|
(±)-Duloxetine-d3 (hydrochloride) is deuterium labeled (±)-Duloxetine (hydrochloride). (±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research[1].
|
-
-
- HY-147306
-
|
Others
|
Neurological Disease
|
ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation .
|
-
-
- HY-12698
-
|
Opioid Receptor
|
Neurological Disease
|
NNC63-0532 is a novel non-peptide nociceptin receptor (ORL1) agonist, with EC50s of 305?nM. NNC63-0532 plays important roles in many disorders such as pain, drug addiction .
|
-
-
- HY-160592
-
|
Sodium Channel
|
Neurological Disease
|
Nav1.8-IN-11 (Example 1) is a Nav1.8 channel inhibitor with a IC50 value of 0.1 nM. Nav1.8-IN-11 can be used in the study of pain disorders .
|
-
-
- HY-155320
-
|
Opioid Receptor
|
Neurological Disease
|
Mu opioid receptor antagonist 7 (compound 24) is a potent and CNS permeable antagonist of µOR (µ-opioid receptor), with an IC50 of 29 ± 3.0 nM. Mu opioid receptor antagonist 7 can be used for the research of pain and opioid use disorder .
|
-
-
- HY-123825
-
-
-
- HY-160591
-
|
Sodium Channel
|
Neurological Disease
|
Nav1.8-IN-10 (Compound 6) is a Nav1.8 channel inhibitor. When the concentration is 4 nM, the percentage blocking rate of Nav1.8 channel is 79.4%. Nav1.8-IN-10 can be used in the study of pain disorders .
|
-
-
- HY-B0161A
-
(S)-Duloxetine hydrochloride; LY-248686 hydrochloride
|
Serotonin Transporter
|
Neurological Disease
|
Duloxetine hydrochloride ((S)-Duloxetine hydrochloride) is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
-
- HY-B0161
-
(S)-Duloxetine; LY248686
|
Serotonin Transporter
|
Neurological Disease
|
Duloxetine is a serotonin-norepinephrine reuptake inhibitor with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD) .
|
-
-
- HY-B0161AS
-
(S)-Duloxetine-d3 (hydrochloride); LY248686-d3 (hydrochloride)
|
Serotonin Transporter
|
Neurological Disease
|
Duloxetine-d3 (hydrochloride) is a deuterium labeled Duloxetine hydrochloride. Duloxetine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD)[1][2].
|
-
-
- HY-118858
-
|
EAAT
|
Neurological Disease
Cancer
|
UCPH-102 is a highly selective EAAT1 inhibitor with an IC50 of 0.43 µM. UCPH-102 exhibits a specific anti-proliferative effect on T-ALL cells. UCPH-102 also shows good blood-brain permeability, which can be used in studies of amyotrophic lateral sclerosis, Alzheimer’s disease, chronic pain and obsessive compulsive disorder .
|
-
-
- HY-151621
-
-
-
- HY-12152
-
NSC 216666
|
nAChR
|
Neurological Disease
Inflammation/Immunology
|
PNU-120596 (NSC 216666) is a potent and selective α7 nAChR positive allosteric modulator (PMA) with an EC50 of 216 nM. PNU-120596 is inactive against α4β2, α3β4, and α9α10 nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research .
|
-
-
- HY-155318A
-
|
Others
|
Endocrinology
|
GPR3 agonist-2(compound 32) is a potent full agonist of G protein-coupled receptor 3, with the IC50of 260 nM .
|
-
-
- HY-143390
-
|
iGluR
|
Neurological Disease
|
NMDA receptor modulator 2 (Compound 1) is a potent NMDA receptor modulator. NMDA receptor modulator 2 can be used for neurological disorder research .
|
-
-
- HY-143391
-
|
iGluR
|
Neurological Disease
|
NMDA receptor modulator 3 (Compound 99) is a potent NMDA receptor modulator. NMDA receptor modulator 3 can be used for neurological disorder research .
|
-
-
- HY-143393
-
|
iGluR
|
Neurological Disease
|
NMDA receptor modulator 4 (Compound 169) is a potent NMDA receptor modulator. NMDA receptor modulator 4 can be used for neurological disorder research .
|
-
-
- HY-143396
-
|
iGluR
|
Neurological Disease
|
NMDA receptor modulator 5 (Compound 195) is a potent NMDA receptor modulator. NMDA receptor modulator 5 can be used for neurological disorder research .
|
-
-
- HY-143397
-
|
iGluR
|
Neurological Disease
|
NMDA receptor modulator 6 (Compound 183) is a potent NMDA receptor modulator. NMDA receptor modulator 6 can be used for neurological disorder research .
|
-
-
- HY-136362
-
|
c-Fms
|
Inflammation/Immunology
Cancer
|
ARRY-382 is a potent, oral and highly selective inhibitor of CSF1R/c-Fms with an IC50 of 9 nM. ARRY-382 can be used for the research of advanced or metastatic cancers .
|
-
-
- HY-122624
-
|
MMP
|
Inflammation/Immunology
|
MMP13-IN-2 is a potent, selective and orally active MMP-13 inhibitor. MMP13-IN-2 exhibits excellent potency for MMP-13 (IC50=0.036 nM) and selectivities (greater than 1,500-fold) over MMP-1, 3, 7, 8, 9, 14, and TACE. MMP13-IN-2 has the ability to block the release of collagen from cartilage in vitro. MMP13-IN-2 has the potential for collagenase related disease research .
|
-
-
- HY-147352
-
|
iGluR
|
Neurological Disease
|
NMDA receptor potentiator-1 (Compound 1368) is a subunit selective NMDA receptor potentiator with IC50s of 4 μM and 5 μM against NR2C and NR2D expression, respectively .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P1238A
-
Neuromedin U (rat) (TFA); Rat neuromedin U-23 TFA
|
Peptides
|
Neurological Disease
|
Neuromedin U, rat TFA is a 23-amino acid brain-gut peptide. Neuromedin U (NMU), through its cognate receptor NMUR2 in the central nervous system, regulates several important physiological functions, including energy balance, stress response, and nociception.
|
-
- HY-P1238
-
Neuromedin U (rat); Rat neuromedin U-23
|
Peptides
|
Neurological Disease
|
Neuromedin U, rat is a 23-amino acid brain-gut peptide. Neuromedin U (NMU), through its cognate receptor NMUR2 in the central nervous system, regulates several important physiological functions, including energy balance, stress response, and nociception.
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-13681S
-
|
Methylprednisolone acetate-d6 is the deuterium labeled Methylprednisolone acetate (HY-13681). Methylprednisolone acetate, a prednisolone derivative, is a corticosteroid hormone. Methylprednisolone acetate can relieve pain and swelling that occurs with arthritis and other joint disorders in vivo .
|
-
-
- HY-B0161ES
-
|
(±)-Duloxetine-d3 (hydrochloride) is deuterium labeled (±)-Duloxetine (hydrochloride). (±)-Duloxetine ((Rac)-Duloxetine) hydrochloride is the racemate of Duloxetine hydrochloride. Duloxetine hydrochloride, a serotonin-norepinephrine reuptake inhibitor, can be used for diabetic neuropathic pain and fibromyalgia as well as major depressive disorder research[1].
|
-
-
- HY-B0161AS
-
|
Duloxetine-d3 (hydrochloride) is a deuterium labeled Duloxetine hydrochloride. Duloxetine hydrochloride is a serotonin-norepinephrine reuptake inhibitor (SNRI) with a Ki of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD)[1][2].
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: